Sensitivity of Stromal Elements from Human Bone Marrow Cells to Cytosine Arabinoside In Vitro

  • E. Elstner
  • H. Goldschmidt
  • M. Wächter
  • R. Ihle
Conference paper
Part of the Haematology and Blood Transfusion / Hämatologie und Bluttransfusion book series (HAEMATOLOGY, volume 31)


Cytosine arabinoside (Ara-C) is one of the most effective agents in the treatment of acute myelogenous leukemia (AML). Recently, low-dose Ara-C therapy has been the subject of topical interest in view of its differentiation-inducing effect on leukemic blast cells. Many patients, however, develop severe aplasia with low-dose Ara-C therapy [1, 6, 10, 11]. The aim of our study was to obtain some information about causes of this aplasia, i.e., to determine whether the lesion is primarily in the hemopoietic stem cells or whether there is any additional damage done to stromal elements.


Acute Myelogenous Leukemia Cytosine Arabinoside Hemopoietic Stem Cell Stromal Element Stromal Layer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Degos L, Castaigne S, Tilly H, Sigaux F, Daniel MT (1985) Treatment of leukemia with low-dose Ara-C. A study of 160 cases. Semin Oncol [Suppl 3] 12(2):196–199Google Scholar
  2. 2.
    Dexter TM, Allen TD, Lajtha LG (1977) Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol 91:335–344PubMedCrossRefGoogle Scholar
  3. 3.
    Elstner E, Schulze E, Ihle R, Stobbe H, Grunze S (1985) Stromal progenitor cells in bone marrow of patients with aplastic anemia. In: Neth R, Gallo R, Greaves MF, Janka G (eds) Haematology and blood transfusion. Springer, Berlin Heidelberg New York Tokyo, pp 168–171 (Modern trends in human leukemia 6)Google Scholar
  4. 4.
    Gartner S, Kaplan HS (1980) Long-term culture of human bone marrow cells. Proc Natl Acad Sci USA 77:4756–4759PubMedCrossRefGoogle Scholar
  5. 5.
    Hays E, Hale L, Villarreal B, Fitchen JM (1982) “Stromal” and hemopoietic stem cell abnormalities in long-term cultures of marrow from busulfan-treated mice. Exp Hematol 10:383–392PubMedGoogle Scholar
  6. 6.
    Jehn U, Bock R de, Haanen C (1984) Clinical trial of low-dose Ara-C in the treatment of acute leukemia and myelodysplasia. Blut 48:255–261PubMedGoogle Scholar
  7. 7.
    Pike BL, Robinson WA (1970) Human bone marrow colony growth in agar-gel. J Cell Physiol 76:77–84PubMedCrossRefGoogle Scholar
  8. 8.
    Raijmakers R, Witte T de, Linssen P, Wessels J, Haanen C (1986) The relation of exposure time and drug concentration in their effect on cloning efficiency after incubation of human bone marrow with cytosine arabinoside. Br J Haematol 62:447–453PubMedCrossRefGoogle Scholar
  9. 9.
    Spriggs D, Griffin J, Wisch J, Kufe D (1985) Clinical pharmacology of low-dose cytosine arabinoside. Blood 65:1087–1089PubMedGoogle Scholar
  10. 10.
    Tilly H, Castaigne S, Bordessoule D, Sigaux F, Faniel M, Monconduit M, Degos L (1985) Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients. Cancer 55:1633–1636PubMedCrossRefGoogle Scholar
  11. 11.
    Tricot G, Bock R de, Dekker AW, Boogaerts MA, Pettermans M, Punt K, Verwilghen RL (1984) Low-dose cytosine arabinoside (Ara-C) in myelodysplastic syndromes. Br J Haematol 58:231–240PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1987

Authors and Affiliations

  • E. Elstner
    • 1
  • H. Goldschmidt
    • 1
  • M. Wächter
    • 1
  • R. Ihle
    • 1
  1. 1.Department of Internal Medicine, Division of HematologyUniversity Hospital (Charité)BerlinGDR

Personalised recommendations